celecoxib has been researched along with prednisolone in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Whitehouse, MW | 1 |
| Baek, HJ; Cha, HS; Jung, HG; Kang, SW; Kim, HA; Koh, EM; Lee, CK; Lee, EY; Lee, YJ; Song, YW; Suh, Y; Yoo, B | 1 |
| Amrite, AC; Edelhauser, HF; Kompella, UB | 1 |
| Abrams, MA; Kossodo, S; Labranche, TP; Listello, JT; Melton, M; Misko, TP; Peterson, JD; Rader, R; Vasquez, KO | 1 |
| Asada, H; Fukumoto, T; Kobayashi, N; Morito, H; Ogawa, K | 1 |
| Gavin, J; Gilmer, JF; Kedziora, K; Kelleher, DP; Keogh, B; Marquez Ruiz, JF; Pigott, M; Windle, H | 1 |
| Brookshire, HL; English, RV; Gift, BW; Gilger, BC; Nadelstein, B; Weigt, AK | 1 |
| Hong, JH; Kim, JS; Ko, JY; Oh, EH; Ro, YS; Shin, JM | 1 |
| Arteaga-Henríquez, G; Gisbert, L; Ramos-Quiroga, JA | 1 |
2 review(s) available for celecoxib and prednisolone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Immunoregulatory and/or Anti-inflammatory Agents for the Management of Core and Associated Symptoms in Individuals with Autism Spectrum Disorder: A Narrative Review of Randomized, Placebo-Controlled Trials.
Topics: Acetylcysteine; Anti-Inflammatory Agents; Autism Spectrum Disorder; Celecoxib; Fatty Acids, Omega-3; Humans; Immunologic Factors; Minocycline; Prednisolone; Randomized Controlled Trials as Topic | 2023 |
1 trial(s) available for celecoxib and prednisolone
| Article | Year |
|---|---|
Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Clematis; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drugs, Chinese Herbal; Female; Humans; Korea; Male; Middle Aged; Pain; Pain Measurement; Phytotherapy; Prednisolone; Prunella; Pyrazoles; Sulfonamides | 2007 |
11 other study(ies) available for celecoxib and prednisolone
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Prostanoids as friends, not foes: further evidence from the interference by cycloxygenase-inhibitory drugs when inducing tolerance to experimental arthritigens in rats.
Topics: Administration, Oral; Animals; Arthritis, Experimental; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Tolerance; Female; Inflammation; Injections, Subcutaneous; Lipids; Pain; Prednisolone; Prostaglandins; Pyrazoles; Rats; Rats, Wistar; Squalene; Sulfonamides; Time Factors | 2005 |
Modeling of corneal and retinal pharmacokinetics after periocular drug administration.
Topics: Animals; Celecoxib; Conjunctiva; Cornea; Cyclooxygenase 2 Inhibitors; Glucocorticoids; Models, Biological; Permeability; Prednisolone; Pyrazoles; Rabbits; Rats; Rats, Inbred BN; Rats, Sprague-Dawley; Retina; Sulfonamides; Validation Studies as Topic | 2008 |
Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Cathepsins; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Disease Progression; Female; Glucocorticoids; Matrix Metalloproteinases; Mice; Mice, Inbred BALB C; Prednisolone; Pyrazoles; Sulfonamides; Tomography, Optical; Treatment Outcome | 2010 |
Drug-induced hypersensitivity syndrome followed by persistent arthritis.
Topics: Anti-Arrhythmia Agents; Arthralgia; Arthritis; Celecoxib; Chronic Disease; Cyclooxygenase 2 Inhibitors; DNA, Viral; Drug Hypersensitivity; Drug Therapy, Combination; Exanthema; Female; Herpesvirus 6, Human; Humans; Matrix Metalloproteinase 3; Mexiletine; Middle Aged; Prednisolone; Pyrazoles; Sulfonamides; Treatment Outcome | 2012 |
A nitrophenyl-based prodrug type for colorectal targeting of prednisolone, budesonide and celecoxib.
Topics: Antineoplastic Agents; Budesonide; Caco-2 Cells; Celecoxib; Cell Membrane Permeability; Clostridium perfringens; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Nitrobenzenes; Nitroreductases; Prednisolone; Prodrugs; Pyrazoles; Sulfonamides | 2013 |
Efficacy of COX-2 inhibitors in controlling inflammation and capsular opacification after phacoemulsification cataract removal.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzophenones; Bromobenzenes; Celecoxib; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Inflammation; Intraocular Pressure; Lenses, Intraocular; Phacoemulsification; Prednisolone | 2015 |
Drug-induced bullous Sweet's syndrome by celecoxib.
Topics: Antirheumatic Agents; Arthralgia; Arthritis, Rheumatoid; Biopsy; Blister; Blood Sedimentation; C-Reactive Protein; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Fluorescent Antibody Technique, Direct; Glucocorticoids; Humans; Leukocyte Count; Lower Extremity; Middle Aged; Prednisolone; Rheumatoid Factor; Skin; Sweet Syndrome; Withholding Treatment | 2016 |